

Sabino De Placido

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/37175/publications.pdf>

Version: 2024-02-01

207
papers

8,493
citations

44069

48
h-index

58581

82
g-index

212
all docs

212
docs citations

212
times ranked

13312
citing authors

#	ARTICLE	IF	CITATIONS
1	Taxane-Based Combinations As Adjuvant Chemotherapy of Early Breast Cancer: A Meta-Analysis of Randomized Trials. <i>Journal of Clinical Oncology</i> , 2008, 26, 44-53.	1.6	389
2	Symptomatic Toxicities Experienced During Anticancer Treatment: Agreement Between Patient and Physician Reporting in Three Randomized Trials. <i>Journal of Clinical Oncology</i> , 2015, 33, 910-915.	1.6	361
3	Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer. <i>Npj Breast Cancer</i> , 2021, 7, 1.	5.2	331
4	Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial. <i>Lancet Oncology</i> , The, 2014, 15, 396-405.	10.7	327
5	Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials. <i>Lancet</i> , The, 2019, 393, 1440-1452.	13.7	260
6	Epithelial-Mesenchymal Transition and Stem Cell Markers in Patients with HER2-Positive Metastatic Breast Cancer. <i>Molecular Cancer Therapeutics</i> , 2012, 11, 2526-2534.	4.1	194
7	Circulating tumor cells as prognostic and predictive markers in metastatic breast cancer patients receiving first-line systemic treatment. <i>Breast Cancer Research</i> , 2011, 13, R67.	5.0	188
8	Perspective on Circulating Tumor Cell Clusters: Why It Takes a Village to Metastasize. <i>Cancer Research</i> , 2018, 78, 845-852.	0.9	169
9	Fluorouracil and dose-dense chemotherapy in adjuvant treatment of patients with early-stage breast cancer: an open-label, 2x2 factorial, randomised phase 3 trial. <i>Lancet</i> , The, 2015, 385, 1863-1872.	13.7	164
10	CDK 4/6 Inhibitors as Single Agent in Advanced Solid Tumors. <i>Frontiers in Oncology</i> , 2018, 8, 608.	2.8	160
11	First-Line Trastuzumab Plus an Aromatase Inhibitor, With or Without Pertuzumab, in Human Epidermal Growth Factor Receptor 2-Positive and Hormone Receptor-Positive Metastatic or Locally Advanced Breast Cancer (PERTAIN): A Randomized, Open-Label Phase II Trial. <i>Journal of Clinical Oncology</i> , 2018, 36, 2826-2835.	1.6	152
12	A Specific miRNA Signature Correlates With Complete Pathological Response to Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 83, 1113-1119.	0.8	149
13	Phase II Study of Sorafenib in Patients With Sunitinib-Refractory Metastatic Renal Cell Cancer. <i>Journal of Clinical Oncology</i> , 2009, 27, 4469-4474.	1.6	131
14	Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysis. <i>Lancet Oncology</i> , The, 2019, 20, 1360-1369.	10.7	131
15	Mechanisms of lapatinib resistance in HER2-driven breast cancer. <i>Cancer Treatment Reviews</i> , 2015, 41, 877-883.	7.7	125
16	Combination of Bevacizumab and Docetaxel in Docetaxel-Pretreated Hormone-Refractory Prostate Cancer: A Phase 2 Study. <i>European Urology</i> , 2008, 54, 1089-1096.	1.9	121
17	Phase II Study of Everolimus in Patients With Thymoma and Thymic Carcinoma Previously Treated With Cisplatin-Based Chemotherapy. <i>Journal of Clinical Oncology</i> , 2018, 36, 342-349.	1.6	120
18	2D and 3D strain for detection of subclinical anthracycline cardiotoxicity in breast cancer patients: a balance with feasibility. <i>European Heart Journal Cardiovascular Imaging</i> , 2017, 18, 930-936.	1.2	118

#	ARTICLE	IF	CITATIONS
19	Preventing Venous Thromboembolism in Ambulatory Cancer Patients: The ONKOTEV Study. <i>Oncologist</i> , 2017, 22, 601-608.	3.7	108
20	Castration-Resistant Prostate Cancer. <i>Drugs</i> , 2010, 70, 983-1000.	10.9	98
21	Toll-like receptors and COVID-19: a two-faced story with an exciting ending. <i>Future Science OA</i> , 2020, 6, FSO605.	1.9	96
22	Circulating tumor cells as early predictors of metastatic spread in breast cancer patients with limited metastatic dissemination. <i>Breast Cancer Research</i> , 2014, 16, 440.	5.0	94
23	High Ki-67 score is indicative of a greater benefit from adjuvant chemotherapy when added to endocrine therapy in Luminal B HER2 negative and node-positive breast cancer. <i>Breast</i> , 2014, 23, 69-75.	2.2	92
24	HER2-enriched subtype and pathological complete response in HER2-positive breast cancer: A systematic review and meta-analysis. <i>Cancer Treatment Reviews</i> , 2020, 84, 101965.	7.7	92
25	Circulating tumor DNA analysis in breast cancer: Is it ready for prime-time?. <i>Cancer Treatment Reviews</i> , 2019, 73, 73-83.	7.7	88
26	Sphingosine Kinase 1 Overexpression Contributes to Cetuximab Resistance in Human Colorectal Cancer Models. <i>Clinical Cancer Research</i> , 2013, 19, 138-147.	7.0	87
27	Hormone Receptor/Human Epidermal Growth Factor Receptor 2-positive breast cancer: Where we are now and where we are going. <i>Cancer Treatment Reviews</i> , 2016, 46, 20-26.	7.7	87
28	Bladder-sparing, combined-modality approach for muscle-invasive bladder cancer. <i>Cancer</i> , 2008, 112, 75-83.	4.1	83
29	Phase II study of docetaxel re-treatment in docetaxel-pretreated castration-resistant prostate cancer. <i>BJU International</i> , 2011, 107, 234-239.	2.5	82
30	Nab-paclitaxel for the treatment of triple-negative breast cancer: Rationale, clinical data and future perspectives. <i>Cancer Treatment Reviews</i> , 2016, 50, 129-141.	7.7	81
31	A comprehensive outlook on intracerebral therapy of malignant gliomas. <i>Critical Reviews in Oncology/Hematology</i> , 2011, 80, 54-68.	4.4	79
32	Cisplatin and 5-fluorouracil in inoperable, stage IV squamous cell carcinoma of the penis. <i>BJU International</i> , 2012, 110, E661-6.	2.5	76
33	Hedgehog signalling pathway orchestrates angiogenesis in triple-negative breast cancers. <i>British Journal of Cancer</i> , 2017, 116, 1425-1435.	6.4	76
34	Fractional microablative CO2 laser for vulvovaginal atrophy in women treated with chemotherapy and/or hormonal therapy for breast cancer: a retrospective study. <i>Menopause</i> , 2016, 23, 1108-1113.	2.0	75
35	Paclitaxel in Pretreated Metastatic Penile Cancer: Final Results of a Phase 2 Study. <i>European Urology</i> , 2011, 60, 1280-1284.	1.9	73
36	Gene expression profiling in breast cancer: A clinical perspective. <i>Breast</i> , 2013, 22, 109-120.	2.2	73

#	ARTICLE	IF	CITATIONS
37	Bevacizumab-related arterial hypertension as a predictive marker in metastatic colorectal cancer patients. <i>Cancer Chemotherapy and Pharmacology</i> , 2011, 68, 1207-1213.	2.3	67
38	Fractional microablative CO2 laser in breast cancer survivors affected by iatrogenic vulvovaginal atrophy after failure of nonestrogenic local treatments: a retrospective study. <i>Menopause</i> , 2018, 25, 657-662.	2.0	65
39	Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2018, 19, 474-485.	10.7	59
40	Overall Survival of CDK4/6-Inhibitor-Based Treatments in Clinically Relevant Subgroups of Metastatic Breast Cancer: Systematic Review and Meta-Analysis. <i>Journal of the National Cancer Institute</i> , 2020, 112, 1089-1097.	6.3	59
41	Activity and Safety of Pegylated Liposomal Doxorubicin as First-Line Therapy in the Treatment of Non-Visceral Classic Kaposi's Sarcoma: A Multicenter Study. <i>Journal of Investigative Dermatology</i> , 2008, 128, 1578-1580.	0.7	57
42	Epidermal growth factor-receptor activation modulates Src-dependent resistance to lapatinib in breast cancer models. <i>Breast Cancer Research</i> , 2014, 16, R45.	5.0	56
43	Urokinase-type plasminogen activator receptor (uPAR) expression enhances invasion and metastasis in RAS mutated tumors. <i>Scientific Reports</i> , 2017, 7, 9388.	3.3	56
44	Third-Line Sorafenib After Sequential Therapy With Sunitinib and mTOR Inhibitors in Metastatic Renal Cell Carcinoma. <i>European Urology</i> , 2010, 58, 906-911.	1.9	55
45	The emerging role of obesity, diet and lipid metabolism in prostate cancer. <i>Future Oncology</i> , 2017, 13, 285-293.	2.4	55
46	Continuing trastuzumab beyond disease progression: outcomes analysis in patients with metastatic breast cancer. <i>Breast Cancer Research</i> , 2008, 10, R60.	5.0	54
47	Strain-oriented strategy for guiding cardioprotection initiation of breast cancer patients experiencing cardiac dysfunction. <i>European Heart Journal Cardiovascular Imaging</i> , 2019, 20, 1345-1352.	1.2	53
48	Features of aggressive breast cancer. <i>Breast</i> , 2015, 24, 594-600.	2.2	52
49	Analysis of Differential miRNA Expression in Primary Tumor and Stroma of Colorectal Cancer Patients. <i>BioMed Research International</i> , 2014, 2014, 1-8.	1.9	49
50	Chemotherapy versus endocrine therapy as first-line treatment in patients with luminal-like HER2-negative metastatic breast cancer: A propensity score analysis. <i>Breast</i> , 2017, 31, 114-120.	2.2	49
51	Crosstalk between bone niche and immune system: Osteoimmunology signaling as a potential target for cancer treatment. <i>Cancer Treatment Reviews</i> , 2015, 41, 61-68.	7.7	48
52	Molecular Mechanism and Clinical Implications of Endocrine Therapy Resistance in Breast Cancer. <i>Oncology</i> , 2009, 77, 23-37.	1.9	47
53	Increased Expression of the Autocrine Motility Factor is Associated With Poor Prognosis in Patients With Clear Cell Renal Cell Carcinoma. <i>Medicine (United States)</i> , 2015, 94, e2117.	1.0	45
54	Recent success and limitations of immune checkpoint inhibitors for cancer: a lesson from melanoma. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2019, 474, 421-432.	2.8	45

#	ARTICLE	IF	CITATIONS
55	Imatinib mesylate in thymic epithelial malignancies. <i>Cancer Chemotherapy and Pharmacology</i> , 2012, 69, 309-315.	2.3	44
56	Modified Glasgow Prognostic Score is Associated With Risk of Recurrence in Bladder Cancer Patients After Radical Cystectomy. <i>Medicine (United States)</i> , 2015, 94, e1861.	1.0	43
57	Poly (ADP-ribose) polymerase inhibitors in solid tumours: Systematic review and meta-analysis. <i>European Journal of Cancer</i> , 2021, 149, 134-152.	2.8	41
58	Extended therapy with letrozole as adjuvant treatment of postmenopausal patients with early-stage breast cancer: a multicentre, open-label, randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2021, 22, 1458-1467.	10.7	41
59	Biomarkers in localized prostate cancer. <i>Future Oncology</i> , 2016, 12, 399-411.	2.4	39
60	Blockade of AP-1 Potentiates Endocrine Therapy and Overcomes Resistance. <i>Molecular Cancer Research</i> , 2016, 14, 470-481.	3.4	39
61	Dose-dense adjuvant chemotherapy in premenopausal breast cancer patients: A pooled analysis of the MIG1 and GIM2 phase III studies. <i>European Journal of Cancer</i> , 2017, 71, 34-42.	2.8	39
62	Adjuvant zoledronic acid and letrozole plus ovarian function suppression in premenopausal breast cancer: HOBOE phase 3 randomised trial. <i>European Journal of Cancer</i> , 2019, 118, 178-186.	2.8	39
63	Potential value of Gleason score in predicting the benefit of cabazitaxel in metastatic castration-resistant prostate cancer. <i>Future Oncology</i> , 2013, 9, 889-897.	2.4	38
64	Approaches for targeting cancer stem cells drug resistance. <i>Expert Opinion on Drug Discovery</i> , 2016, 11, 1201-1212.	5.0	38
65	Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study's primary analysis of 2573 patients. <i>European Journal of Cancer</i> , 2017, 82, 237-246.	2.8	38
66	Multiple treatment lines and prognosis in metastatic colorectal cancer patients. <i>Cancer and Metastasis Reviews</i> , 2019, 38, 307-313.	5.9	38
67	Clinical Outcomes of Perioperative Chemotherapy in Patients With Locally Advanced Penile Squamous-Cell Carcinoma: Results of a Multicenter Analysis. <i>Clinical Genitourinary Cancer</i> , 2017, 15, 548-555.e3.	1.9	37
68	Statin use and survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone or enzalutamide after docetaxel failure: the international retrospective observational STABEN study. <i>Oncotarget</i> , 2018, 9, 19861-19873.	1.8	37
69	Src inhibitors act through different mechanisms in Non-Small Cell Lung Cancer models depending on EGFR and RAS mutational status. <i>Oncotarget</i> , 2015, 6, 26090-26103.	1.8	37
70	Cytometric and biochemical characterization of human breast cancer cells reveals heterogeneous myoepithelial phenotypes. <i>Cytometry Part A: the Journal of the International Society for Analytical Cytology</i> , 2012, 81A, 960-972.	1.5	36
71	Cytosolic phosphorylated EGFR is predictive of recurrence in early stage penile cancer patients: a retrospective study. <i>Journal of Translational Medicine</i> , 2013, 11, 161.	4.4	36
72	Increased risk of bladder cancer in critical areas at high pressure of pollution of the Campania region in Italy: A systematic review. <i>Critical Reviews in Oncology/Hematology</i> , 2015, 96, 534-541.	4.4	35

#	ARTICLE	IF	CITATIONS
73	Total metabolic tumor volume by 18F-FDG PET/CT for the prediction of outcome in patients with non-small cell lung cancer. <i>Annals of Nuclear Medicine</i> , 2019, 33, 937-944.	2.2	35
74	First-line systemic therapy for metastatic castration-sensitive prostate cancer: An updated systematic review with novel findings. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 157, 103198.	4.4	35
75	New Perspectives in the Therapy of Castration Resistant Prostate Cancer. <i>Current Drug Targets</i> , 2012, 13, 1676-1686.	2.1	34
76	Recent Advances on Pathophysiology, Diagnostic and Therapeutic Insights in Cardiac Dysfunction Induced by Antineoplastic Drugs. <i>BioMed Research International</i> , 2015, 2015, 1-14.	1.9	34
77	Metabolic and anthropometric changes in early breast cancer patients receiving adjuvant therapy. <i>Breast Cancer Research and Treatment</i> , 2015, 154, 127-132.	2.5	33
78	Clinical Characteristics of Metastatic Prostate Cancer Patients Infected with COVID-19 in South Italy. <i>Oncology</i> , 2020, 98, 743-747.	1.9	33
79	Outcomes Associated with First-Line anti-PD-1/ PD-L1 agents vs. Sunitinib in Patients with Sarcomatoid Renal Cell Carcinoma: A Systematic Review and Meta-Analysis. <i>Cancers</i> , 2020, 12, 408.	3.7	32
80	Pegylated liposomal doxorubicin as second-line therapy in the treatment of patients with advanced classic Kaposi sarcoma. <i>Cancer</i> , 2008, 112, 1147-1152.	4.1	31
81	Artificial neural network analysis of circulating tumor cells in metastatic breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 2011, 129, 451-458.	2.5	31
82	Long-term survival and BRCA status in male breast cancer: a retrospective single-center analysis. <i>BMC Cancer</i> , 2016, 16, 375.	2.6	31
83	Statin Use and Survival in Patients with Metastatic Castration-resistant Prostate Cancer Treated with Abiraterone Acetate. <i>European Urology Focus</i> , 2018, 4, 874-879.	3.1	30
84	Combination of docetaxel and cetuximab for penile cancer. <i>Anti-Cancer Drugs</i> , 2012, 23, 573-577.	1.4	29
85	Peg-filgrastim and cabazitaxel in prostate cancer patients. <i>Anti-Cancer Drugs</i> , 2013, 24, 84-89.	1.4	29
86	Neoadjuvant Treatment in Locally Advanced Pancreatic Cancer (LAPC) Patients with FOLFIRINOX or Gemcitabine NabPaclitaxel: A Single-Center Experience and a Literature Review. <i>Cancers</i> , 2019, 11, 981.	3.7	29
87	Oncological care organisation during COVID-19 outbreak. <i>ESMO Open</i> , 2020, 5, e000853.	4.5	29
88	Predictors of efficacy of androgen-receptor-axis-targeted therapies in patients with metastatic castration-sensitive prostate cancer: A systematic review and meta-analysis. <i>Critical Reviews in Oncology/Hematology</i> , 2020, 151, 102992.	4.4	28
89	Human epidermal growth factor receptor 2 dual blockade with trastuzumab and pertuzumab in real life: Italian clinical practice versus the CLEOPATRA trial results. <i>Breast</i> , 2018, 38, 86-91.	2.2	27
90	Metabolic syndrome and early stage breast cancer outcome: results from a prospective observational study. <i>Breast Cancer Research and Treatment</i> , 2020, 182, 401-409.	2.5	27

#	ARTICLE	IF	CITATIONS
91	Efficacy of rituximab in gastric diffuse large B cell lymphoma patients. <i>World Journal of Gastroenterology</i> , 2010, 16, 2526.	3.3	27
92	Predictive Factors of Complete Response to Neoadjuvant Chemoradiotherapy in Patients with Rectal Cancer. <i>Oncology</i> , 2010, 78, 369-375.	1.9	26
93	Isoquercetin as an Adjunct Therapy in Patients With Kidney Cancer Receiving First-Line Sunitinib (QUASAR): Results of a Phase I Trial. <i>Frontiers in Pharmacology</i> , 2018, 9, 189.	3.5	26
94	Targeting bone metastatic cancer: Role of the mTOR pathway. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2014, 1845, 248-254.	7.4	25
95	Phase II trial of cisplatin plus prednisone in docetaxel-refractory castration-resistant prostate cancer patients. <i>Cancer Chemotherapy and Pharmacology</i> , 2011, 67, 1455-1461.	2.3	24
96	Urologic malignancies: advances in the analysis and interpretation of clinical findings. <i>Future Science OA</i> , 2021, 7, FSO674.	1.9	24
97	Weekly docetaxel versus CMF as adjuvant chemotherapy for elderly breast cancer patients: Safety data from the multicentre phase 3 randomised ELDA trial. <i>Critical Reviews in Oncology/Hematology</i> , 2008, 66, 171-180.	4.4	23
98	Increased overall survival independent of RECIST response in metastatic breast cancer patients continuing trastuzumab treatment: evidence from a retrospective study. <i>Breast Cancer Research and Treatment</i> , 2011, 128, 147-154.	2.5	23
99	An adjusted indirect comparison of everolimus and sorafenib therapy in sunitinib-refractory metastatic renal cell carcinoma patients using repeated matched samples. <i>Expert Opinion on Pharmacotherapy</i> , 2011, 12, 1491-1497.	1.8	23
100	An Italian cost-effectiveness analysis of paclitaxel albumin (nab-paclitaxel) versus conventional paclitaxel for metastatic breast cancer patients: the COSTANza study. <i>ClinicoEconomics and Outcomes Research</i> , 2013, 5, 125.	1.9	23
101	Carboplatin plus etoposide in heavily pretreated castration-resistant prostate cancer patients. <i>Future Oncology</i> , 2014, 10, 1353-1360.	2.4	23
102	Adjuvant Treatment for Locally Advanced Rectal Cancer Patients After Preoperative Chemoradiotherapy: When, and for Whom?. <i>Clinical Colorectal Cancer</i> , 2014, 13, 185-191.	2.3	23
103	Prognostic and Predictive Factors in Patients with Advanced Penile Cancer Receiving Salvage (2nd or) Tj ETQq1 1 0.784314 rgBT /Over 487.	3.5	23
104	<p>Treating advanced breast cancer with metronomic chemotherapy: what is known, what is new and what is the future?</p>. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 2989-2997.	2.0	23
105	Impact of Metformin Use and Diabetic Status During Adjuvant Fluoropyrimidine-Oxaliplatin Chemotherapy on the Outcome of Patients with Resected Colon Cancer: A TOSCA Study Subanalysis. <i>Oncologist</i> , 2019, 24, 385-393.	3.7	23
106	The evolving role of monoclonal antibodies in the treatment of patients with advanced renal cell carcinoma: a systematic review. <i>Expert Opinion on Biological Therapy</i> , 2016, 16, 1387-1401.	3.1	22
107	PI3K/mTOR Inhibitors in the Treatment of Luminal Breast Cancer. Why, When and to Whom. <i>Breast Care</i> , 2017, 12, 290-294.	1.4	21
108	Fast Detection of a BRCA2 Large Genomic Duplication by Next Generation Sequencing as a Single Procedure: A Case Report. <i>International Journal of Molecular Sciences</i> , 2017, 18, 2487.	4.1	20

#	ARTICLE	IF	CITATIONS
109	Definition of High-Risk Early Hormone-Positive HER2 ⁻ Negative Breast Cancer: A Consensus Review. <i>Cancers</i> , 2022, 14, 1898.	3.7	20
110	Phase 1/2 study of intravenous paclitaxel and oral cyclophosphamide in pretreated metastatic urothelial bladder cancer patients. <i>Cancer</i> , 2009, 115, 517-523.	4.1	19
111	Randomised phase 3 open-label trial of first-line treatment with gemcitabine in association with docetaxel or paclitaxel in women with metastatic breast cancer: a comparison of different schedules and treatments. <i>BMC Cancer</i> , 2013, 13, 164.	2.6	19
112	FOLFIRI in patients with locally advanced or metastatic pancreatic or biliary tract carcinoma. <i>Anti-Cancer Drugs</i> , 2013, 24, 980-985.	1.4	19
113	The 2nd meeting of the Campania Society of Oncology Immunotherapy (SCITO): focus on hepatocellular carcinoma, kidney and bladder cancer. , 2016, 4, .		18
114	Predictors of Outcomes in Patients with EGFR-Mutated Non-Small Cell Lung Cancer Receiving EGFR Tyrosine Kinase Inhibitors: A Systematic Review and Meta-Analysis. <i>Cancers</i> , 2019, 11, 1259.	3.7	18
115	Assessment of Total, PTEN ⁺ , and AR-V7+ Circulating Tumor Cell Count by Flow Cytometry in Patients with Metastatic Castration-Resistant Prostate Cancer Receiving Enzalutamide. <i>Clinical Genitourinary Cancer</i> , 2021, 19, e286-e298.	1.9	18
116	Cabazitaxel in castration resistant prostate cancer with brain metastases: 3 case reports. <i>World Journal of Clinical Cases</i> , 2014, 2, 228.	0.8	18
117	Combined effect of obesity and diabetes on early breast cancer outcome: a prospective observational study. <i>Oncotarget</i> , 2017, 8, 115709-115717.	1.8	18
118	Targeting fibroblast growth factor receptor pathway in breast cancer. <i>Current Opinion in Oncology</i> , 2015, 27, 452-456.	2.4	17
119	Urotensin II receptor on preoperative biopsy is associated with upstaging and upgrading in prostate cancer. <i>Future Oncology</i> , 2015, 11, 3091-3098.	2.4	17
120	Endocrine-Based Treatments in Clinically-Relevant Subgroups of Hormone Receptor-Positive/HER2-Negative Metastatic Breast Cancer: Systematic Review and Meta-Analysis. <i>Cancers</i> , 2021, 13, 1458.	3.7	17
121	Third-Line Chemotherapy for Metastatic Urothelial Cancer. <i>Medicine (United States)</i> , 2015, 94, e2297.	1.0	16
122	It is no longer the time to disregard thyroid metastases from breast cancer: a case report and review of the literature. <i>BMC Cancer</i> , 2018, 18, 146.	2.6	16
123	Dexamethasone-Sparing Regimens with Oral Netupitant and Palonosetron for the Prevention of Emesis Caused by High-Dose Cisplatin: A Randomized Noninferiority Study. <i>Oncologist</i> , 2021, 26, e1854-e1861.	3.7	16
124	Clinical activity and cardiac tolerability of non-pegylated liposomal doxorubicin in breast cancer: a synthetic review. <i>Tumori</i> , 2011, 97, 690-2.	1.1	15
125	Everolimus induces Met inactivation by disrupting the FKBP12/Met complex. <i>Oncotarget</i> , 2016, 7, 40073-40084.	1.8	15
126	EGFR mutational status in penile cancer. <i>Expert Opinion on Therapeutic Targets</i> , 2013, 17, 501-505.	3.4	14

#	ARTICLE	IF	CITATIONS
127	Lack of Cumulative Toxicity Associated With Cabazitaxel Use in Prostate Cancer. <i>Medicine (United States)</i> , 2021, 100, e01154.	1.0	14
128	Demographic, tumor and clinical features of clinical trials versus clinical practice patients with HER2-positive early breast cancer: results of a prospective study. <i>Journal of Cancer Research and Clinical Oncology</i> , 2016, 142, 669-678.	2.5	14
129	Phase II open-label study of bevacizumab combined with neoadjuvant anthracycline and taxane therapy for locally advanced breast cancer. <i>Breast</i> , 2013, 22, 470-475.	2.2	13
130	Impact of COVID-19 outbreak on cancer immunotherapy in Italy: a survey of young oncologists. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020, 146, e001154.		13
131	Combined Imaging With 18F-FDG-PET/CT and 111In-Labeled Octreotide SPECT for Evaluation of Thymic Epithelial Tumors. <i>Clinical Nuclear Medicine</i> , 2013, 38, 354-358.	1.3	12
132	Pretreatment Serum Concentration of Vitamin D and Breast Cancer Characteristics: A Prospective Observational Mediterranean Study. <i>Clinical Breast Cancer</i> , 2017, 17, 559-563.	2.4	12
133	Exemestane and Everolimus combination treatment of hormone receptor positive, HER2 negative metastatic breast cancer: A retrospective study of 9 cancer centers in the Campania Region (Southern Italy). <i>Journal of Cancer Research and Clinical Oncology</i> , 2021, 147, e001154.	1.0	12
134	Anthracyclines Strike Back: Rediscovering Non-Pegylated Liposomal Doxorubicin in Current Therapeutic Scenarios of Breast Cancer. <i>Cancers</i> , 2021, 13, 4421.	3.7	12
135	Activity and toxicity of paclitaxel in pretreated metastatic penile cancer patients. <i>Anti-Cancer Drugs</i> , 2009, 20, 277-280.	1.4	11
136	Heterogeneity of SSTR2 Expression Assessed by ⁶⁸ Ga-DOTATOC PET/CT Using Coefficient of Variation in Patients with Neuroendocrine Tumors. <i>Journal of Nuclear Medicine</i> , 2022, 63, 1509-1514.	5.0	11
137	In vitro expansion of human breast cancer epithelial and mesenchymal stromal cells: optimization of a coculture model for personalized therapy approaches. <i>Molecular Cancer Therapeutics</i> , 2007, 6, 3091-3100.	4.1	10
138	Management of Germ Cell Tumors During the Outbreak of the Novel Coronavirus Disease-19 Pandemic: A Survey of International Expertise Centers. <i>Oncologist</i> , 2020, 25, e1509-e1515.	3.7	10
139	EMPACT Syndrome Associated with Phenobarbital. <i>Dermatitis</i> , 2013, 24, 37-39.	1.6	9
140	Prognostic role of chemotherapy-induced neutropenia in first-line treatment of advanced ovarian cancer. A pooled analysis of MITO2 and MITO7 trials. <i>Gynecologic Oncology</i> , 2019, 154, 83-88.	1.4	9
141	Optimising triage procedures for patients with cancer needing active anticancer treatment in the COVID-19 era. <i>ESMO Open</i> , 2020, 5, e000885.	4.5	9
142	A review of the use of next generation sequencing methodologies to identify biomarkers of resistance to CDK4/6 inhibitors in ER+/HER2- breast cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 157, 103191.	4.4	9
143	Inadequate health-related quality of life assessment and reporting in phase III clinical trials of immune checkpoint inhibitors in solid cancers: A systematic review. <i>Critical Reviews in Oncology/Hematology</i> , 2022, 172, 103649.	4.4	9
144	Prevalence of Sarcopenia in Women with Breast Cancer. <i>Nutrients</i> , 2022, 14, 1839.	4.1	9

#	ARTICLE	IF	CITATIONS
145	Nab-paclitaxel for the management of triple-negative metastatic breast cancer. <i>Anti-Cancer Drugs</i> , 2015, 26, 117-122.	1.4	8
146	High-dose fotemustine in temozolomide-pretreated glioblastoma multiforme patients. <i>Medicine (United States)</i> , 2018, 97, e11254.	1.0	8
147	Prognostic role of sarcopenia in metastatic colorectal cancer patients during first-line chemotherapy: A retrospective study. <i>World Journal of Clinical Oncology</i> , 2021, 12, 355-366.	2.3	8
148	Rapidly progressive disease in a castration-resistant prostate cancer patient after cabazitaxel discontinuation. <i>Anti-Cancer Drugs</i> , 2015, 26, 236-239.	1.4	7
149	FOLFIRINOX after first-line gemcitabine-based chemotherapy in advanced pancreatic cancer: a retrospective comparison with FOLFOX and FOLFIRI schedules. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592094797.	3.2	7
150	Second line trastuzumab emtansine following horizontal dual blockade in a real-life setting. <i>Oncotarget</i> , 2020, 11, 2083-2091.	1.8	7
151	Is There a Standard Chemotherapeutic Regimen for Hormone-Refractory Prostate Cancer? Present and Future Approaches in the Management of the Disease. <i>Tumori</i> , 2003, 89, 349-360.	1.1	6
152	Time required to start multicentre clinical trials within the Italian Medicine Agency programme of support for independent research. <i>Journal of Medical Ethics</i> , 2015, 41, 799-803.	1.8	6
153	Epigenetic Silencing of <i>THY1</i> Tracks the Acquisition of the Notch-EGFR Signaling in a Xenograft Model of CD44+/CD24low/CD90+ Myoepithelial Cells. <i>Molecular Cancer Research</i> , 2019, 17, 628-641.	3.4	6
154	Effectiveness of abiraterone acetate plus prednisone in chemotherapy-naïve patients with metastatic castration-resistant prostate cancer in a large prospective real-world cohort: the ABItude study. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592096872.	3.2	6
155	EFFECT: a randomized phase II study of efficacy and impact on function of two doses of nab-paclitaxel as first-line treatment in older women with advanced breast cancer. <i>Breast Cancer Research</i> , 2020, 22, 83.	5.0	6
156	Netupitant/palonosetron (NEPA) and dexamethasone for prevention of emesis in breast cancer patients receiving adjuvant anthracycline plus cyclophosphamide: a multi-cycle, phase II study. <i>BMC Cancer</i> , 2020, 20, 232.	2.6	6
157	Effect of dose-dense adjuvant chemotherapy in hormone receptor positive/HER2-negative early breast cancer patients according to immunohistochemically defined luminal subtype: an exploratory analysis of the GIM2 trial. <i>European Journal of Cancer</i> , 2020, 136, 43-51.	2.8	6
158	Khorana score and thromboembolic risk in stage II-III colorectal cancer patients: a post hoc analysis from the adjuvant TOSCA trial. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883591989985.	3.2	6
159	Composite risk and benefit from adjuvant dose-dense chemotherapy in hormone receptor-positive breast cancer. <i>Npj Breast Cancer</i> , 2021, 7, 82.	5.2	6
160	Long-Term Outcomes in Uveal Melanoma After Ruthenium-106 Brachytherapy. <i>Frontiers in Oncology</i> , 2021, 11, 754108.	2.8	6
161	The Influence of Prednisone on the Efficacy of Cabazitaxel in Men with Metastatic Castration-Resistant Prostate Cancer. <i>Journal of Cancer</i> , 2017, 8, 2663-2668.	2.5	5
162	A New Horizon of Liquid Biopsy in Thymic Epithelial Tumors: The Potential Utility of Circulating Cell-Free DNA. <i>Frontiers in Oncology</i> , 2020, 10, 602153.	2.8	5

#	ARTICLE	IF	CITATIONS
163	Long term deficiency of vitamin D in germ cell testicular cancer survivors. <i>Oncotarget</i> , 2018, 9, 21078-21085.	1.8	5
164	Breast cancer subtypes according to body mass index and insulin resistance.. <i>Journal of Clinical Oncology</i> , 2014, 32, 571-571.	1.6	5
165	Can high-dose fotemustine reverse MGMT resistance in glioblastoma multiforme?. <i>Journal of Neuro-Oncology</i> , 2010, 100, 311-319.	2.9	4
166	PSA declines and survival in patients with metastatic castration-resistant prostate cancer treated with enzalutamide. <i>Medicine (United States)</i> , 2017, 96, e6817.	1.0	4
167	Clinical features and psychological aspects of the decision-making process in stage I testicular germ cell tumors. <i>Future Oncology</i> , 2018, 14, 1591-1599.	2.4	4
168	Unexpected ovarian activity in premenopausal breast cancer survivors treated with exemestane and GnRH analogues. <i>Breast Journal</i> , 2019, 25, 1310-1311.	1.0	4
169	Targeted next-generation sequencing identifies genomic abnormalities potentially driving the prognosis of early-stage invasive lobular breast carcinoma patients stratified according to a validated clinico-pathological model. <i>Breast</i> , 2020, 50, 56-63.	2.2	4
170	Case Report: Detection of a Novel Germline PALB2 Deletion in a Young Woman With Hereditary Breast Cancer: When the Patient's Phenotype History Doesn't Lie. <i>Frontiers in Oncology</i> , 2021, 11, 602523.	2.8	4
171	Addition of erlotinib to fluoropyrimidine-oxaliplatin-based chemotherapy with or without bevacizumab: Two sequential phase I trials. <i>Experimental and Therapeutic Medicine</i> , 2011, 2, 449-455.	1.8	3
172	Combination of a Toll-like receptor 9 agonist with everolimus interferes with the growth and angiogenic activity of renal cell carcinoma. <i>Oncolmunology</i> , 2013, 2, e25123.	4.6	3
173	The evolving landscape in advanced penile cancer. <i>Future Science OA</i> , 2015, 1, FSO9.	1.9	3
174	Treatment options in HR+/HER2- advanced breast cancer patients pretreated with nonsteroidal aromatase inhibitors: what does current evidence tell us?. <i>Future Oncology</i> , 2015, 11, 975-981.	2.4	3
175	Use of FOLFIRINOX or Nab-Paclitaxel Plus Gemcitabine for the Treatment of Locally Advanced Pancreatic Adenocarcinoma: A Single Institution Observational Study. <i>Cancers</i> , 2021, 13, 4939.	3.7	3
176	The Impact of Translational Research in Breast Cancer Care: Can we Improve the Therapeutic Scenario?. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2018, 18, 832-836.	1.7	3
177	Luminal-like HER2-negative stage IA breast cancer: a multicenter retrospective study on long-term outcome with propensity score analysis. <i>Oncotarget</i> , 2017, 8, 112816-112824.	1.8	3
178	Adjuvant FOLFOX-4 in patients with radically resected gastric cancer: Tolerability and prognostic factors. <i>Experimental and Therapeutic Medicine</i> , 2010, 1, 611-617.	1.8	2
179	Non-small cell lung cancer: from targeted therapy to tailored therapy. <i>Expert Opinion on Pharmacotherapy</i> , 2012, 13, 1817-1819.	1.8	2
180	Authors reply: an adjusted indirect comparison of everolimus and sorafenib therapy in sunitinib-refractory metastatic renal cell carcinoma patients using repeated matched samples. <i>Expert Opinion on Pharmacotherapy</i> , 2012, 13, 1079-1080.	1.8	2

#	ARTICLE	IF	CITATIONS
181	Issues of banking breast cancer cells to generate mammospheres. <i>Cell and Tissue Banking</i> , 2013, 14, 153-158.	1.1	2
182	Long-term disease control with lapatinib and capecitabine in a patient with HER2-positive metastatic breast cancer pretreated with trastuzumab and trastuzumab-emtansine. <i>Tumori</i> , 2013, 99, e131-e133.	1.1	2
183	Cancer prevalence in the city of Naples: Contribution of the GP database analyses to the cancer registries network. <i>Molecular and Clinical Oncology</i> , 2013, 1, 726-732.	1.0	2
184	Using cumulative toxicity to identify the optimal second-line targeted therapy in patients with metastatic renal cell carcinoma: what's new?. <i>Future Oncology</i> , 2014, 10, 845-850.	2.4	2
185	Docetaxel Rechallenge in a Heavily Pretreated Patient With Castration-Resistant Prostate Cancer. <i>Medicine (United States)</i> , 2016, 95, e2754.	1.0	2
186	Two novel sequence variants in MSH2 gene in a patient who underwent cancer genetic counseling for a very early-onset epithelial ovarian cancer. <i>Hereditary Cancer in Clinical Practice</i> , 2016, 14, 18.	1.5	2
187	Discordance in RAS Mutations between Primary Colon Tumor and Metastases: A Real Event or a Matter of Methodology?. <i>International Journal of Biological Markers</i> , 2017, 32, 474-477.	1.8	2
188	Systemic treatment of malignant gastrointestinal neuroectodermal tumour after childhood neuroblastoma. <i>Anti-Cancer Drugs</i> , 2019, 30, 959-963.	1.4	2
189	Triple-negative (TNBC) metastatic breast cancer (MBC) patients (pts): Is chemotherapy (CHT) choice influenced by adjuvant (adj) treatments? Results from the GIM-13 AMBRA study.. <i>Journal of Clinical Oncology</i> , 2019, 37, e12549-e12549.	1.6	2
190	BRCA1/2 NGS Somatic Testing in Clinical Practice: A Short Report. <i>Genes</i> , 2021, 12, 1917.	2.4	2
191	Combination of Cytotoxic Drugs for Patients with HER2-Negative Metastatic Breast Cancer. <i>Combination Products in Therapy</i> , 2013, 3, 25-37.	1.1	1
192	Everolimus-based therapy in patients with hormone receptor-positive, HER2- advanced breast cancer: management considerations. <i>Future Oncology</i> , 2015, 11, 2251-2254.	2.4	1
193	Role of sphingosine kinase 1 (SphK1) on cetuximab resistance in colorectal cancer models.. <i>Journal of Clinical Oncology</i> , 2012, 30, e13509-e13509.	1.6	1
194	Palbociclib added to ongoing endocrine therapy for hormone receptor-positive HER2-negative metastatic breast cancer: A case report series. <i>Molecular and Clinical Oncology</i> , 2020, 12, 456-460.	1.0	1
195	Anti-EGFR target therapy in advanced thymic epithelial tumors.. <i>Journal of Clinical Oncology</i> , 2019, 37, 8567-8567.	1.6	1
196	Evaluation of a Four-Gene Panel for Hereditary Cancer Risk Assessment. <i>Genes</i> , 2022, 13, 682.	2.4	1
197	Immunological signature of patients with thymic epithelial tumors.. <i>Journal of Clinical Oncology</i> , 2022, 40, 8589-8589.	1.6	1
198	Dose-Dense FEC Followed by Dose-Dense Ixabepilone as Neoadjuvant Treatment for Breast Cancer Patients: A Feasibility Study. <i>Oncologist</i> , 2013, 18, 924-925.	3.7	0

#	ARTICLE	IF	CITATIONS
199	What have we learned from immunotherapy? Report from the 3rd and 4th meetings of the Campania Society of Oncology Immunotherapy (SCITO). , 2016, 4, .		0
200	Multicenter Single-Arm, Two-Stage Phase 2 Study of Panitumumab in Patients With Cetuximab-Refractory Metastatic Colorectal Cancer: The PACER Trial. Clinical Colorectal Cancer, 2020, 19, 270-276.	2.3	0
201	Pneumonitis in patients with thymoma and Good's syndrome.. Journal of Clinical Oncology, 2021, 39, e20595-e20595.	1.6	0
202	Bevacizumab maintenance in metastatic colorectal cancer: How long?. World Journal of Clinical Cases, 2014, 2, 717.	0.8	0
203	Risk factors for cancer-related venous thromboembolism in ambulatory patients.. Journal of Clinical Oncology, 2014, 32, e20625-e20625.	1.6	0
204	Progression-free survival (PFS) and overall survival (OS) in HER2-ve advanced breast cancer (ABC) patients (pts) according to the molecular subtype in the era of modern agents: Results from the GIM-13 AMBRA study.. Journal of Clinical Oncology, 2019, 37, e12528-e12528.	1.6	0
205	Abstract P3-09-03: Single nucleotide polymorphisms of aromatase gene (<i>CYP19A1</i>) and toxicity of adjuvant aromatase inhibitors: A translational, prospective study. Cancer Research, 2022, 82, P3-09-03-P3-09-03.	0.9	0
206	FOLFIRINOX or nab-paclitaxel plus gemcitabine in metastatic pancreatic adenocarcinoma: an observational study. Future Oncology, 0, , .	2.4	0
207	Impaired seroconversion after SARS-COV-2 mRNA vaccine in patients with thymic epithelial tumors.. Journal of Clinical Oncology, 2022, 40, 8588-8588.	1.6	0